- Home
- RGCO vs MDWD Comparison
RGCO vs MDWD Comparison
Compare RGCO & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGCO
- MDWD
- Stock Information
- Founded
- RGCO 1912
- MDWD 2000
- Country
- RGCO United States
- MDWD Israel
- Employees
- RGCO N/A
- MDWD N/A
- Industry
- RGCO Oil & Gas Production
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- RGCO Utilities
- MDWD Health Care
- Exchange
- RGCO Nasdaq
- MDWD Nasdaq
- Market Cap
- RGCO N/A
- MDWD 184.8M
- IPO Year
- RGCO N/A
- MDWD 2014
- Fundamental
- Price
- RGCO $20.36
- MDWD $18.06
- Analyst Decision
- RGCO
- MDWD Strong Buy
- Analyst Count
- RGCO 0
- MDWD 2
- Target Price
- RGCO N/A
- MDWD $32.00
- AVG Volume (30 Days)
- RGCO 10.7K
- MDWD 66.5K
- Earning Date
- RGCO 04-30-2025
- MDWD 03-19-2025
- Dividend Yield
- RGCO 4.07%
- MDWD N/A
- EPS Growth
- RGCO N/A
- MDWD N/A
- EPS
- RGCO 1.17
- MDWD N/A
- Revenue
- RGCO $87,511,366.00
- MDWD $19,720,000.00
- Revenue This Year
- RGCO $7.25
- MDWD $10.15
- Revenue Next Year
- RGCO $5.62
- MDWD $25.62
- P/E Ratio
- RGCO $17.21
- MDWD N/A
- Revenue Growth
- RGCO N/A
- MDWD N/A
- 52 Week Low
- RGCO $18.38
- MDWD $12.78
- 52 Week High
- RGCO $24.20
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- RGCO 50.54
- MDWD 52.66
- Support Level
- RGCO $19.97
- MDWD $16.00
- Resistance Level
- RGCO $20.94
- MDWD $17.49
- Average True Range (ATR)
- RGCO 0.59
- MDWD 0.96
- MACD
- RGCO 0.02
- MDWD 0.08
- Stochastic Oscillator
- RGCO 67.36
- MDWD 63.01
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.